Evidence map›Paper›PMID 38690137›Full record

ArticleGlobal health & medicine2024

Prevalence, characteristics, and virologic correlations of hepatitis delta (D) among patients with hepatitis B surface antigen in Mongolia.

Sarantuya Gidaagaya, Akinori Rokuhara, Masaya Sugiyama, Sumiya Dorj, Batnasan Barsuren, Bira Namdag, Batmunkh Munkhbat, Shinichi Oka, Masashi Mizokami

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Analysis of a PCORnetCommunications medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sarantuya GidaagayaDepartment of Gastroenterology and Hepatology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Akinori RokuharaGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Masaya SugiyamaDepartment of Viral Pathogenesis and Controls, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Sumiya DorjLaboratory Department, Intermed Hospital, Ulaanbaatar, Mongolia.
Batnasan BarsurenDepartment of Molecular Biology, Bonavita Clinical Laboratory, Ulaanbaatar, Mongolia.
Bira NamdagDepartment of Gastroenterology and Hepatology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Batmunkh MunkhbatDepartment of Graduate Education, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Shinichi OkaAIDS Clinical Center, National Center for Global Health and Medicine, Toyama, Tokyo, Japan.
Masashi MizokamiGenome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
National Center for Global Health and Medicine · JPMongolian National University · MNInternational University of Health and Welfare · JPMongolian University of Life Sciences · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical and biochemical features of hepatitis delta virus (HDV) infections in Mongolia remain largely unknown. We aimed to investigate the clinical characteristics of HDV patients in Mongolia using several markers. The 143 hepatitis B surface antigen (HBsAg)-positive patients were divided into 122 HDV-positive and 21 HDV-negative patients by HDV RNA positivity. Subgroup analysis was performed between hepatitis B e antigen (HBeAg)-positive and -negative HDV-positive patients. Liver function, quantitative HBsAg (qHBsAg), anti-HDV Immunoglobulin (Ig) M, Mac-2 binding protein glycosylation isomer (M2BPGi), hepatitis B virus (HBV) DNA level, and HDV RNA level were tested. HDV RNA was positive in 85.3% (122/143) of patients showing anti-HDV IgG. Liver disease activity was higher in HDV-positive patients than in HDV-negative patients. The HDV-positive group included a higher proportion of patients with high qHBsAg and M2BPGi levels (

Indexed as

anti-HDV IgMHBeAghepatitis B virushighly sensitive HDV RNA assayM2BPGiquantitative HBsAg

Identifiers

PMID38690137
PMCPMC11043131
OpenAlexW4390658577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.